June 29 (Reuters) - Eli Lilly and Co said on Thursday it would acquire Sigilon Therapeutics Inc in an all-cash deal that could be worth more than $300 million, excluding shares held by Lilly. (Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)